MPR Weekly Dose podcast

11:37

REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome.

1
MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed 12:48

há 14 dias12:48

12:48

New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP.

1
MPR Weekly Dose Podcast #224 — Strategy for High-Threshold Peanut Allergy; Emblaveo Approved for Complicated Infections; New Formulation of Evrysdi; FDA Fast Tracks Designations Investigational… 12:31

há 21 dias12:31

12:31

Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal infections; new tablet formulation of Evrysdi; FDA fast tracks investigational agents for Alzheimer disease and cannabis use disorder.

1
MPR Weekly Dose 223 — Diabetes Devices Alert Warning; Continuous Apomorphine Device Approved for Parkinson Disease; Symbravo Approved; New Pain Tx; Propranolol May Cut Stroke Risk 15:21

há 27 dias15:21

15:21

FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease ‘off’ periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.…

1
MPR Weekly Dose 222 — Ozempic expanded approval; MS treatment gets Boxed Warning; Monotherapy approval for Spravato; Alzheimer Tx maintenance regimen; Enhertu new Breast CA indication 13:50

há 5 weeks13:50

13:50

Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains maintenance regimen; Enhertu gains new Breast CA indication.

1
MPR Weekly Dose Podcast #221 — OTC Phenylephrine Removal; Schizophrenia Drug Efficacy Data; FDA Vote on Sotagliflozin; IV Ibuprofen vs Ketorolac; Semaglutide Improves Liver Fibrosis 13:16

há 17 weeks13:16

13:16

The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.…

1
Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies 25:08

há 17 weeks25:08

25:08

Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients.

1
MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared 11:28

há 21 weeks11:28

11:28

Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screening.…

1
MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple’s Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis 13:18

há 24 weeks13:18

13:18

The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple’s sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis

1
MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine 12:21

há 25 weeks12:21

12:21

New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine.

1
MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard 12:46

há 26 weeks12:46

12:46

CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system.

1
MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk… 12:38

há 28 weeks12:38

12:38

Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.…

1
MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD 14:19

há 29 weeks14:19

14:19

New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression.

1
MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication 17:44

há 30 weeks17:44

17:44

The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication.

1
MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval 14:09

há 31 weeks14:09